News
UPDATE: Lilly’s Oral Weight Loss Drug Underdelivers, But Executives See Real World Opportunity
Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ bear scenario for the oral med. Executives brushed off the concerns and said the drug will still have a wide advantage on the market.
The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...
Novo took the active ingredient of Ozempic, semaglutide, and rebranded it as Wegovy to be used specifically for weight loss.
Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...
By Christy Santhosh (Reuters) -Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United ...
Weight-loss drugs significantly improve health, though they’re also tied to increased spending on other medical care that’s ...
Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...
Weight-loss drugs are expected to pull in more than $150 billion in industry-wide revenue by the early 2030s, thanks to the ...
Orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral therapy showed a 13.6% drop in weight.
Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug ...
Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...
The drugmaker released its second-quarter earnings report early Wednesday as it vowed to cut costs amid intensifying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback